Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant durvalumab plus concurrent chemoradiotherapy in potentially resectable stage IIIA non-small cell lung cancer
KCT0003103Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: pathologic complete response rate. Started Feb 2019; status: completed.
02
Drugs
durvalumabpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003103.